Gary Raskob to Warfarin
This is a "connection" page, showing publications Gary Raskob has written about Warfarin.
Connection Strength
4.087
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36.
Score: 0.503
-
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16.
Score: 0.493
-
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost. 2014 Jun; 12(6):824-30.
Score: 0.443
-
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S.
Score: 0.214
-
Anticoagulant Therapy for Mechanical Heart Valves - Unmet Need Persists. NEJM Evid. 2023 Jul; 2(7):EVIDe2300106.
Score: 0.208
-
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thromb Haemost. 2019 Mar; 119(3):461-466.
Score: 0.153
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
Score: 0.141
-
Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice. Ann Intern Med. 1997 Nov 01; 127(9):839-41.
Score: 0.141
-
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793.
Score: 0.133
-
Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
Score: 0.131
-
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45.
Score: 0.130
-
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164.
Score: 0.130
-
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61.
Score: 0.126
-
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015 Dec; 13(12):2187-91.
Score: 0.122
-
Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9.
Score: 0.119
-
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15.
Score: 0.105
-
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
Score: 0.104
-
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9.
Score: 0.093
-
Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300.
Score: 0.064
-
Redefining clinical venous thromboembolism phenotypes: a?novel approach using latent class analysis. J Thromb Haemost. 2023 03; 21(3):573-585.
Score: 0.050
-
Long-term anticoagulant therapy prevents recurrent venous thromboembolism. J R Soc Med. 1982 Apr; 75(4):289.
Score: 0.048
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
Score: 0.038
-
The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21.
Score: 0.035
-
Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
Score: 0.033
-
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 Sep 27; 116(4):747-53.
Score: 0.032
-
Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9.
Score: 0.030
-
Cost effectiveness of diagnosis of deep vein thrombosis in symptomatic patients. Thromb Haemost. 1995 Jul; 74(1):189-96.
Score: 0.030
-
Anticoagulants and thrombolysis in the treatment of pulmonary embolism. Curr Opin Pulm Med. 1995 Jul; 1(4):291-7.
Score: 0.030
-
Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
Score: 0.028
-
A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6.
Score: 0.027
-
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808.
Score: 0.026
-
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510.
Score: 0.022
-
Predicting the daily prothrombin time response to warfarin. Ther Drug Monit. 1990 May; 12(3):246-9.
Score: 0.021
-
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
Score: 0.020
-
Anticoagulant therapy for venous thromboembolism. Prog Hemost Thromb. 1989; 9:1-27.
Score: 0.019
-
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82.
Score: 0.017
-
A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA. 1984 Jul 13; 252(2):235-9.
Score: 0.014
-
Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992 Aug; 152(8):1589-95.
Score: 0.006
-
Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 03; 322(18):1260-4.
Score: 0.005
-
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81.
Score: 0.003